Show simple item record

dc.contributor.authorAcemoglu, Daron
dc.contributor.authorGruber, Jonathan
dc.contributor.authorChaloupka, Frank J.
dc.contributor.authorWarner, Kenneth E.
dc.contributor.authorLaux, Fritz
dc.contributor.authorMax, Wendy
dc.contributor.authorNewhouse, Joseph
dc.contributor.authorSchelling, Thomas
dc.contributor.authorSindeclair, Jody
dc.date.accessioned2015-03-11T15:07:47Z
dc.date.available2015-03-11T15:07:47Z
dc.date.issued2014-12
dc.date.submitted2014-10
dc.identifier.issn0964-4563
dc.identifier.urihttp://hdl.handle.net/1721.1/95942
dc.description.abstractThe Family Smoking Prevention and Tobacco Control Act of 2009 gave the Food and Drug Administration (FDA) regulatory authority over cigarettes and smokeless tobacco products and authorised it to assert jurisdiction over other tobacco products. As with other Federal agencies, FDA is required to assess the costs and benefits of its significant regulatory actions. To date, FDA has issued economic impact analyses of one proposed and one final rule requiring graphic warning labels (GWLs) on cigarette packaging and, most recently, of a proposed rule that would assert FDA’s authority over tobacco products other than cigarettes and smokeless tobacco. Given the controversy over the FDA's approach to assessing net economic benefits in its proposed and final rules on GWLs and the importance of having economic impact analyses prepared in accordance with sound economic analysis, a group of prominent economists met in early 2014 to review that approach and, where indicated, to offer suggestions for an improved analysis. We concluded that the analysis of the impact of GWLs on smoking substantially underestimated the benefits and overestimated the costs, leading the FDA to substantially underestimate the net benefits of the GWLs. We hope that the FDA will find our evaluation useful in subsequent analyses, not only of GWLs but also of other regulations regarding tobacco products. Most of what we discuss applies to all instances of evaluating the costs and benefits of tobacco product regulation and, we believe, should be considered in FDA's future analyses of proposed rules.en_US
dc.description.sponsorshipRobert Wood Johnson Foundation (Grant 71484)en_US
dc.language.isoen_US
dc.publisherBMJ Publishing Groupen_US
dc.relation.isversionofhttp://dx.doi.org/10.1136/tobaccocontrol-2014-052022en_US
dc.rightsCreative Commons Attribution Non Commercialen_US
dc.rights.urihttp://creativecommons.org/licenses/by-nc/4.0/en_US
dc.sourceBMJ Publishing Groupen_US
dc.titleAn evaluation of the FDA's analysis of the costs and benefits of the graphic warning label regulationen_US
dc.typeArticleen_US
dc.identifier.citationChaloupka, Frank J., Kenneth E. Warner, Daron Acemoglu, Jonathan Gruber, Fritz Laux, Wendy Max, Joseph Newhouse, Thomas Schelling, and Jody Sindelar. “An Evaluation of the FDA’s Analysis of the Costs and Benefits of the Graphic Warning Label Regulation.” Tobacco Control 24, no. 2 (December 30, 2014): 112–119.en_US
dc.contributor.departmentMassachusetts Institute of Technology. Department of Economicsen_US
dc.contributor.mitauthorAcemoglu, Daronen_US
dc.contributor.mitauthorGruber, Jonathanen_US
dc.relation.journalTobacco Controlen_US
dc.eprint.versionFinal published versionen_US
dc.type.urihttp://purl.org/eprint/type/JournalArticleen_US
eprint.statushttp://purl.org/eprint/status/PeerRevieweden_US
dspace.orderedauthorsChaloupka, Frank J.; Warner, Kenneth E.; Acemoglu, Daron; Gruber, Jonathan; Laux, Fritz; Max, Wendy; Newhouse, Joseph; Schelling, Thomas; Sindelar, Jodyen_US
dc.identifier.orcidhttps://orcid.org/0000-0002-9877-3065
dc.identifier.orcidhttps://orcid.org/0000-0003-0908-7491
mit.licensePUBLISHER_CCen_US
mit.metadata.statusComplete


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record